MRTX News and Press, Mirati Therapeutics Inc. From 04/30/21

With a flurry of ongoing clinical studies, you can bet that Mirati has much more catalysts to power further upsides. As a KRAS inhibitor, Adagrasib is generating robust data for a variety of cancers, including lungs, colorectal, pancreatic, etc. Sitravatinib is the other lead medi...

The following slide deck was published by Mirati Therapeutics, Inc. in conjunction with this event. For further details see: Mirati Therapeutics Inc (MRTX) Presents at AACR Virtual Meeting 2021 - Slideshow

BeiGene (BGNE) presents clinical data on tislelizumab, in combination with sitravatinib being jointly developed with Mirati Therapeutics (MRTX) at the American Association for Cancer Research ((AACR)) Annual Meeting 2021.Data presented were from two cohorts of Phase 1b trial in patients ...

Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models Internally discovered PRMT5 program represents a potential first-in-class approach to specifically target MTAP-deleted...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...

Mirati Therapeutics (MRTX) announced that its Board of Directors has elected Shalini Sharp as a new independent director.Sharp has more than 25 years of financial and corporate strategy experience in the life sciences industry.Most recently, she was the Chief Financial Off...

Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director PR Newswire SAN DIEGO , March 31, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced its Board of Directors has elec...

With an estimated ~$530B war chest in total, large biopharma companies will continue to drive M&A activity in 2021, the analysts at Goldman Sachs predicted in a new analysis of the sector.Noting a ~110% YoY rise in deal volumes in February including ~221% YoY growth in U.S. mid-cap deals,...

Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021 PR Newswire SAN DIEGO , March 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-...

Mirati Therapeutics (MRTX): Q4 GAAP EPS of -$2.08 beats by $0.17.Revenue of $1.71M (+222.6% Y/Y) beats by $1.41M.Cash, cash equivalents, and short-term investments of $1.4B.Press Release For further details see: Mirati Therapeutics EPS beats by $0.17, beats on revenue